Acetylcholinesterase inhibitors (AChEIs) are pivotal in managing Alzheimer's disease and other dementias by impeding the enzyme acetylcholinesterase. This enzyme normally degrades acetylcholine, a neurotransmitter crucial for cognitive functions like memory and learning. In Alzheimer's, a deficit of acetylcholine arises from the loss of cholinergic neurons. AChEIs help sustain higher acetylcholine levels in the brain, offering temporary relief from cognitive symptoms such as memory loss and confusion. While they do not halt or reverse disease progression, these medications can significantly enhance quality of life. Common AChEIs include donepezil, rivastigmine, and galantamine, each with potential side effects like nausea and insomnia. Effective management requires ongoing monitoring and adjustments by healthcare providers to optimize therapeutic benefits.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neurophysiological change and cognitive response to levetiracetam in Alzheimer disease: Testing the missing mechanistic link
Christopher Hubler, Emergent Neural Systems Institute for Research, United States
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia